Pam Taub, MD, FACC, FASPC

The panelists stress the significance of a comprehensive approach to patient care.

Cardiometabolic Medicine: Seeing the Patient as a Whole

Videos

The panelists stress the significance of a comprehensive approach to patient care, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.

Michael Koren, MD addresses the challenges posed by prior authorization.

Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

Video content above is prompted by the following questions:

How does your office handle payer approval/prior authorization for lipid lower medication? Are there any tips to help with getting approval?

How is help with co pay assistance programs coordinated in your practice to help increase accessibility and affordability?

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

The panel explores issues surrounding medication adherence and the potential for improved patient engagement.

Medication Adherence in Patients with High LDL Cholesterol

Adherence remains a big hurdle in lipid management. A well-known rule in medicine is, “the more educated the patient, the more adherent the patient.”

How do you implement patient education on cardiovascular health into your practice? What are persistent gaps?

How are the novel molecular treatments affecting adherence to lipid lowering therapies? (examples from your practice?)

What is still needed on a larger/national scale to educate patients as well as providers on the importance of lipid screening and the availability of safe and effective medication?

The panel explores issues surrounding medication adherence and the potential for improved patient engagement. They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes.

Diabetes, GLP-1, and Lipid Reduction

Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.

Pam Taub, MD, FACC, FASPC

Articles